European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

Descripción del proyecto

Un método de diagnóstico y seguimiento novedoso para las enfermedades inmunitarias

Las enfermedades inflamatorias inmunitarias (IMID, por sus siglas en inglés) incluyen patologías con diferentes etiologías, que se caracterizan por tener rutas inflamatorias comunes que llevan a la inflamación, desencadenada por una desregulación de la respuesta inmunitaria normal. Las IMID son heterogéneas en cuanto a la evolución de la enfermedad y la respuesta a tratamientos específicos. Los biomarcadores son importantes para realizar una medicina de precisión. A través del proyecto financiado con fondos europeos ImmUniverse, un consorcio internacional transdisciplinar estudia la función de la comunicación cruzada entre el microentorno tisular y las células inmunitarias en la progresión de las enfermedades y su respuesta al tratamiento de dos IMID: la colitis ulcerosa y la dermatitis atópica. El proyecto llevará el diagnóstico de las IMID y el seguimiento de la respuesta al tratamiento a un nuevo nivel poniendo en práctica una metodología de biopsia líquida no invasiva combinada con ensayos de biomarcadores en circulación.

Objetivo

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

HUMANITAS UNIVERSITY
Aportación neta de la UEn
€ 1 988 088,25
Dirección
VIA RITA LEVI MONTALCINI SNC
20090 Pieve Emanuele
Italia

Ver en el mapa

Región
Nord-Ovest Lombardia Milano
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 098 088,25

Participantes (30)